Upstream Bio, Inc. (NASDAQ:UPB) Given Consensus Rating of “Moderate Buy” by Brokerages

Upstream Bio, Inc. (NASDAQ:UPB) has earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $38.20.

A number of brokerages have weighed in on UPB. HC Wainwright assumed coverage on Upstream Bio in a research report on Wednesday, June 3rd. They set a “buy” rating and a $36.00 target price for the company. Mizuho reduced their price target on Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, May 14th. Weiss Ratings lowered Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. Evercore lowered Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price target for the company. in a research report on Friday, March 27th. Finally, Wall Street Zen lowered Upstream Bio from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in UPB. AQR Capital Management LLC acquired a new position in Upstream Bio during the 1st quarter valued at about $115,000. Woodline Partners LP boosted its stake in shares of Upstream Bio by 5.8% in the first quarter. Woodline Partners LP now owns 557,063 shares of the company’s stock worth $3,409,000 after buying an additional 30,552 shares during the last quarter. Creative Planning purchased a new stake in shares of Upstream Bio in the second quarter worth about $154,000. JPMorgan Chase & Co. boosted its stake in shares of Upstream Bio by 8.4% in the second quarter. JPMorgan Chase & Co. now owns 16,469 shares of the company’s stock worth $181,000 after buying an additional 1,275 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of Upstream Bio by 83.0% in the second quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock worth $35,000 after buying an additional 1,440 shares during the last quarter.

Upstream Bio Stock Down 6.1%

Shares of NASDAQ UPB opened at $6.28 on Thursday. The business has a fifty day simple moving average of $8.90 and a two-hundred day simple moving average of $17.05. The firm has a market cap of $341.76 million, a PE ratio of -2.16 and a beta of 1.10. Upstream Bio has a twelve month low of $6.25 and a twelve month high of $33.68.

Upstream Bio (NASDAQ:UPB) last issued its earnings results on Wednesday, May 13th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.02). The firm had revenue of $1.03 million for the quarter, compared to the consensus estimate of $1.03 million. Upstream Bio had a negative net margin of 4,718.96% and a negative return on equity of 43.82%. On average, research analysts expect that Upstream Bio will post -2.99 earnings per share for the current year.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.